Second generation basal insulins, such as degludec and glargine 300, which are characterized by an extended duration of action and by a low pronounced pharmacokinetic peak, have shown a reduced risk of hypoglycemia while maintaining a good glycemic control, compared to other basal insulins [8,9,10]. This evidence concerns the gene INS and Hypoglycemia.